BREAKING NEWS: The FDA has just approved a revolutionary pill version of Wegovy, offering a needle-free and cost-effective solution for weight management. The new oral medication will be available in the US starting in January 2024 at a price of just $149 per month, significantly lower than the current injectable version that costs approximately $1,350 monthly.
This approval marks a historic moment, making Wegovy the first pill-based GLP-1 medication specifically cleared for weight loss. The active ingredient, semaglutide, remains the same as in the injectable form, which has gained popularity due to its effectiveness.
According to drugmaker Novo Nordisk, the pill is designed for adults struggling with obesity or those who are overweight with at least one weight-related health condition. It also aims to reduce the risk of serious cardiovascular issues, including heart attacks and strokes.
In a recent clinical trial involving over 300 participants, patients taking the Wegovy pill lost an impressive average of 16.6% of their body weight over a period of approximately 64 weeks. These results are comparable to those achieved with the injectable version, solidifying the pill’s potential as a powerful weight-loss tool.
Mike Doustdar, CEO of Novo Nordisk, emphasized the convenience of this new option: “With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection.”
The demand for GLP-1 weight-loss drugs has surged, as highlighted by a recent survey from health policy research group KFF. In a study conducted in late October and early November, approximately 12% of adult Americans reported using a GLP-1 drug such as Wegovy or Ozempic to manage weight or treat chronic conditions. This figure has increased by 6% since early 2022, showcasing a growing trend in the medication’s uptake.
However, many users face financial challenges. The KFF survey revealed that nearly half of those on GLP-1 medications find them difficult to afford, even with insurance coverage.
The Wegovy pill’s launch is set to provide a more accessible alternative for those seeking effective weight management solutions. As Novo Nordisk prepares for the rollout, more details on coverage and savings options will be announced as the launch date approaches.
Stay tuned for further updates on this developing story as Wegovy transitions to a pill format, reshaping the landscape of weight-loss treatments in the US.
